The effects of COX-1 selective inhibitors in attenuating tumor growth in vivo are remarkable [15], whereas, COX-2 selective inhibitors have potent antineoplastic effects in vivo in preclinical models of various solid malignancies [3,10]. This evidence concerns the gene PTGS2 and neoplasm.